Dr. Kemp received a BA in Biology from Case Western Reserve University, an MS in Fisheries Toxicology from Oregon State University and PhD in Experimental Oncology from the University of Wisconsin, Madison. His PhD thesis focused on the genetic and hormonal basis of hepatocellular carcinoma using mouse models. He did postdoctoral research with Allan Balmain at the Beatson Institute for Cancer Research in Glasgow Scotland studying the role of Hras and p53 in multistage cancer using mouse models. He has been at the Fred Hutchinson Cancer Research Center for over 23 years where he studied the role of tumor suppressor genes including p19/Arf, Atm, Cdkn1b/p27 and Ctcf in cancer progression. He is currently using functional genomic approaches to identify new cancer drug targets using a range of patient derived tumor models. Learn more about Dr. Kemp
Dr. Lui is a translational research scientist with broad experience in cancer biology and drug development. Her current work aims to identify, validate, and develop novel targeted therapies for chemo-resistant ovarian cancer by utilizing functional genomics, high-throughput screening methods, and patient-derived tumor models to target key driver genes. She is a recipient of the Ann and Sol Schreiber Mentored Investigator Award (2018) from the Ovarian Cancer Research Fund Alliance, and is also involved in CTD2 network and industry collaborations.Prior to joining the Kemp laboratory, Dr. Lui interned at the Pfizer Oncology Research Unit in San Diego, CA, and worked at the Centenary Institute in Sydney, Australia. She received her PhD in Medicine and BSc (Adv) (Hons I) in Pharmacology from the University of Sydney.
Dr. Shigeta is a postdoctoral fellow in the Kemp lab. While engaging in clinical practice as a gynecologic oncologist, he finished his postgraduate studies in Japan in 2016 at Tohoku University School of Medicine. He worked on elucidating the mechanism of ovarian cancer carcinogenesis in his postgraduate training. Shogo joined the Kemp lab after earning his PhD to further expand his research focus. His research interest is on the development of novel targeted therapies for ovarian cancer through high-throughput siRNA screens.
Kay Gurley started her career in labs focused on Transplantation Immunology. She worked in labs at Brigham and Women’s Hospital, McGill University, the Royal Prince Alfred Hospital in Sydney and at Stanford University. After working at a biotech start up for two years, she decided to return to academia. She relocated to Seattle where she became the first employee of the Kemp Lab. She has worked on various projects starting with mouse models of cancer particularly focusing on the repair genes DNA-PKcs and ATM. She discovered a synthetic lethality between Atm and DNA-PKcs in embryogenesis. Other projects included ATM’s role in apoptosis after irradiation, and DNA-PK’s role in Acute GI syndrome. Currently she is validating novel targets in mouse squamous cell carcinomas and patient-derived breast cancer cells that were discovered using siRNA screens.
Russell Moser is currently working to identify novel therapeutic targets for pancreatic ductal adenocarcinoma (PDAC) as part of an NCI-funded program Cancer Target Discovery and Development (CTD2). He received his Bachelor of Science in Biochemistry and Molecular Biology from the University of Wisconsin - Madison.